Completed PHASE1 INTERVENTIONAL 5-arm NCT01932437

Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers

A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular Doses of ETI-204 in Adult Volunteers

Sponsor: Elusys Therapeutics

Conditions Inhalational Anthrax

Interventions ETI-204 Placebo

Updated 7 times since 2017 Last updated: May 2, 2019 Started: Jul 26, 2013 Primary completion: Jul 3, 2014 Completion: Jul 3, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01932437, this PHASE1 trial focuses on Inhalational Anthrax and remains completed. Sponsored by Elusys Therapeutics, it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jun 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Elusys Therapeutics

Data source: Elusys Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States